^
    Back
    Association details:
    Biomarker:ALK E1210K
    Cancer:Non Small Cell Lung Cancer
    Drug:Ensacove (ensartinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    AACR-II 2020
    Title:

    Abstract 2997: Longitudinal circulating tumor DNA (ctDNA) analysis predicts response and reveals the resistance mechanisms of ensartinib in ALK+ NSCLC patients (pts) progressed on crizotinib: Updated analysis of a phase II clinical trial

    Published date:
    05/15/2020
    Excerpt:
    Multivariable Cox regression revealed that high level of ctDNA amount and TP53 mutations at BL was significantly associated with poor PFS independently... We observed G1269A, G1202R and E1210K as the major resistant mutations to ensartinib.
    DOI:
    10.1158/1538-7445.AM2020-2997